Sumatriptan is named as an intervention in 2 current clinical trials in our Canada, Mexico and Egypt registers. 2 are recruiting patients now. The most common phase is Observational. The sponsor with the most trials is Duke University (1). The most-studied condition is Lactating Women on Select DOI. The EU clinical trials register (CTIS) separately lists 1 authorised or ongoing trial.
Of the three regulators tracked here, the first to approve Sumatriptan was the US, on 28 Dec 1992.
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
Protections still running for marketed products containing Sumatriptan, as listed by the regulators. Expired patents and exclusivities, and discontinued products, are not shown.
Reproduced from the FDA Orange Book and Purple Book (checked 28 Sep 2026) and the European Commission's Union Register of medicinal products (CC BY 4.0; the EU expiry date is calculated exactly as the Commission's register displays it). Listed patents and dates are as submitted to or published by the regulator and may not reflect litigation, invalidation, settlements, lapsed fees or later extensions. This is not legal advice or a freedom-to-operate opinion, and it does not say when a generic or biosimilar will launch.
From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
| Study | Phase | Status | Lead sponsor | Registers |
|---|
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Authorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Sumatriptan. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
The headache- and migraine-inducing effects of pitolisant in women with migraine without aura
2026-525521-20-00 · CTIS ↗ · Nervous System Diseases
|
Phase 1 | Authorised | Syddansk Universitet (University of Southern Denmark) | Denmark |
The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
11 single-substance products containing Sumatriptan on the HPRA medicines list.
| Lead sponsor | Trials |
|---|---|
| Duke University | 1 |
| Tanta University | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Canada | 1 | 1 |
| Clinical trials in Mexico | 1 | 1 |
| Clinical trials in Egypt | 1 | 1 |
| EU register (CTIS) | 1 | — |
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
2 current trials in our Canada, Mexico and Egypt registers name Sumatriptan as a drug or biological intervention, as of the registry sync on 4 October 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 2 trials are recruiting: 1 with sites in Canada, 1 with sites in Mexico and 1 with sites in Egypt. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Duke University (1) and Tanta University (1). The number in brackets is how many trials each organisation leads.
Yes. The HPRA medicines list includes 11 single-substance products containing Sumatriptan, for example Imigran 10 mg Nasal Spray, Solution (GlaxoSmithKline (Ireland) Limited). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
The registers we track list 1 entry for Sumatriptan: 1 German notice. Shortages are product- and country-specific; check with a pharmacist.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Sumatriptan works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Sumatriptan works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Sumatriptan (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 4 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.
